Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-18T23:04:44.996Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of hepatitis C virus infection in intravenous drug users

Published online by Cambridge University Press:  24 June 2014

Matthew L Cowan  and
James D. Maxwell
Matthew L Cowan
Affiliation:
Institute of Liver Studies, King’s College Hospital, London, UK
James D. Maxwell*
Affiliation:
Section of Gastroenterology, St George’s, University of London, London, UK
*
James Douglas Maxwell, St George’s, University of London, London SW17 0RE, UK. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Hepatitis C virus (HCV) infection is common among intravenous drug users, and because of the long latent period, HCV liver disease is set to increase.

Objectives:

We sought to examine practice guidelines regarding treatment of HCV in drug users and to review the evidence for current practices.

Methods:

A structured search of the Pubmed database, websites of the National Institute for Clinical Excellence and national and international expert groups and opinion of independent experts in the field.

Results and Conclusions:

All those infected with HCV need to be assessed to ascertain whether they have active ongoing viral replication and the extent of liver damage. HCV-infected individuals should be educated about the modes of transmission and means of reducing the risk of infecting others. They should also be advised to avoid cofactors (especially alcohol) that accelerate the progression of liver disease. Specific treatment with antivirals can cause viral clearance and prevent the progression of liver disease. Therapy is effective in those on opiate-replacement treatments and also in motivated individuals who continue to use intravenous drugs. The decision whether to treat drug users should be made jointly by specialists in the management of viral hepatitis and addiction on a case-by-case basis. Current combination drug regimens are expensive but are claimed to be cost-effective, and are certainly much less costly than managing end-stage liver disease. In addition to satisfactory sustained viral response rates, other benefits such as a beneficial effect on drug habit, self-esteem and rehabilitation have been reported. Encouraging suitable drug users to take-up and comply with treatment seems to be more easily achieved in supportive drug dependency unit settings (rather than the more formal surroundings of a hospital clinic).

Keywords

hepatitis C virusintravenous drug usetherapy
Type
Review Article
Information
Acta Neuropsychiatrica , Volume 18 , Issue 5 , October 2006 , pp. 183 - 192
Copyright
Copyright © 2006 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Choo, QL, Kuo, G, Weiner, AJ, Overby, LR, Bradley, DW, Houghton, M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362. CrossRefGoogle ScholarPubMed
World Health Organisation. Hepatitis C: global prevalence – update. Wkly Epidemiol Rec 1997;72:341–344. Google Scholar
Alter, MJ, Kruszon-Moran, D, Nainan, OVet al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556–562. CrossRefGoogle ScholarPubMed
Booth, JCL, O’Grady, J, Neuberger, J. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl I): i1–i21. CrossRefGoogle ScholarPubMed
Alter, MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62s–65s. CrossRefGoogle ScholarPubMed
Ramsay, ME, Balogun, MA, Harris, HE. Epidemiology and health burden of hepatitis C in the UK. In: Bassendine, M, Foster, G, Miles, A, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003: 15–29. Google Scholar
Judd, A, Hickman, M, Jones, Set al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. Br Med J 2005;330:24–25. CrossRefGoogle ScholarPubMed
Simmonds, P, Alberti, A, Alter, HJet al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321–1324. CrossRefGoogle ScholarPubMed
Rai, R, Wilson, LE, Astemborski, J, Ananaia, Fet al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:1247–1255. CrossRefGoogle ScholarPubMed
Ryder, SD. The natural history of hepatitis C infection. In: Bassendine, M, Foster, G, Miles, A, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003:3–14. Google Scholar
Kanai, K, Kako, M, Okamoto, H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543. CrossRefGoogle ScholarPubMed
Tsubota, A, Chayama, K, Ikeda, Ket al. Factors predictive of response to interferon-therapy in hepatitis C virus infection. Hepatology 1994;19:1088–1094. CrossRefGoogle Scholar
Alberti, A, Morsila, G, Chemello, Let al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697–698. CrossRefGoogle ScholarPubMed
Ryder, SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451–455. CrossRefGoogle ScholarPubMed
Sobesky, R, Mathurin, P, Charlotte, Fet al. Modelling the effect of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378–386. CrossRefGoogle Scholar
McCaughan, GW, George, J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004;53:318–321. CrossRefGoogle ScholarPubMed
Wright, M, Goldin, R, Fabre, AMet al. Measurement and determinants of the natural history of liver fibrosis in hepatitis c virus infection. Gut 2003;52:574–579. CrossRefGoogle ScholarPubMed
Bataller, R, North, KE, Brenner, DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493–502. CrossRefGoogle ScholarPubMed
Fattovich, G, Giustina, G, Degos, Fet al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;1112:436–472. Google Scholar
Tsukuma, H, Hiyama, T, Tanaka, Set al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Eng J Med 1993;328:1797–1801. CrossRefGoogle ScholarPubMed
Foster, GR, Goldin, RD, Thomas, HC. Chronic hepatitis C virus infection causes a significant reduction in the quality of life in the absence of cirrhosis. Hepatology 1998;27:209–212. CrossRefGoogle ScholarPubMed
Wessely, S, Pariente, C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002;32:1–10. CrossRefGoogle ScholarPubMed
Forton, DM, Thomas, HC, Murphy, CAet al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433–439. CrossRefGoogle Scholar
Forton, DM, Allsop, JM, Main, J, Foster, GR, Thomas, HC, Taylor-Robinson, SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38–39. CrossRefGoogle ScholarPubMed
Kramer, L, Bauer, E, Funk, Get al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002;37:349–354. CrossRefGoogle ScholarPubMed
Radkowski, M, Wilkinson, J, Nowicki, Met al. Search for hepatitis C virus negative strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600–608. CrossRefGoogle ScholarPubMed
Hadziyannis, S. Non hepatic manifestations of chronic HCV infection. J Viral Hepat 1997;4:1–17. Google Scholar
Strader, DB, Wright, T, Thomas, DL, Seeff, LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147–1171. CrossRefGoogle ScholarPubMed
National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 – June 10–12, 2002. Hepatology 2002;36:s3–s20. Google ScholarPubMed
Puoti, M, Zonaro, A, Ravaggi, A, Marin, MG, Castelnuovo, F, Cariani, E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992;16:877–881. CrossRefGoogle ScholarPubMed
Pawlotsky, JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(Suppl 1):S65–S73. CrossRefGoogle ScholarPubMed
Rice, P. Screening and lab diagnosis of HCV. Acta Neuropsychiatrica 2006 [In press].Google Scholar
Alberti, A, Chumeck, N, Collins, Set al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615–624. CrossRefGoogle ScholarPubMed
Terjung, B, Lemnitzer, I, Dumoulin, FLet al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;67:138–145. CrossRefGoogle ScholarPubMed
Regev, A, Berho, M, Jeffers, LJet al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614–2618. CrossRefGoogle ScholarPubMed
The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15–20. CrossRefGoogle ScholarPubMed
Afdhal, NH, Nunes, D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160–1174. CrossRefGoogle ScholarPubMed
Joseph, AE, Saveryuttu, SH, Al-Sam, S, Cook, MG, Maxwell, JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26–31. CrossRefGoogle ScholarPubMed
Castera, L, Vergniol, J, Foucher, Jet al. Prospective comparison of transient elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–350. CrossRefGoogle ScholarPubMed
Lim, AKP, Taylor-Robinson, SD, Patel, Net al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005;54:128–133. CrossRefGoogle ScholarPubMed
Robaeys, G, Buntinx, F, Bottieau, Eet al. Guidelines for the management of chronic hepatitis C in patients infected after substance abuse. Acta Gatroenterol Belg 2005;68:38–45. Google Scholar
Herrine, SK, Friedman, LS. Divining the role of liver biopsy in hepatitis C. J Hepatol 2005;43:374–376. CrossRefGoogle ScholarPubMed
Green, ST, Mohsen, AH, McKendrick, MWet al. Potential for hepatitis C transmission among non-needle/syringe sharing Sheffield drug injectors through the sharing of drug preparation paraphernalia. Commun Dis Public Health 2001;4:38–41. Google ScholarPubMed
Edlin, BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36(Suppl 1): S210–S219. CrossRefGoogle ScholarPubMed
Gotz, HM, Van Doornum, G, Niesters, HG, Den Hollander, JG, Thio, HB, De Zwart, O. A cluster of acute hepatitis C virus infection among men who have sex with men – results from contact tracing and public health implications. AIDS 2005;19:969–974. CrossRefGoogle ScholarPubMed
Akahane, Y, Kojima, M, Sugai, Yet al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994;51:338–343. Google Scholar
Ohto, H, Terazawa, S, Sasaki, Net al. Transmission of hepatitis C virus from mothers to infants. N Eng J Med 1994;330:744–750. CrossRefGoogle ScholarPubMed
Giovanni, M, Tagger, A, Ribero, MLet al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166. CrossRefGoogle Scholar
Resti, M, Azarri, C, Galli, Let al. Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicentre study of 1372 mother-infant pairs. J Infect Dis 2002;185:567–572. CrossRefGoogle Scholar
Ogasawara, S, Kage, M, Kosai, K-Iet al. Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet 1993;341:561. CrossRefGoogle ScholarPubMed
Vento, S, Garofano, T, Rezini, Cet al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Eng J Med 1998;338:286–290. CrossRefGoogle ScholarPubMed
Tsai, JF, Jeng, JE, Ho, MS, Chang, WY, Lin, ZY, Tsai, JH. Independent and additive effect modification of hepatitis B and C virus infection on the development of chronic hepatitis. J Hepatol 1996;24:271–276. CrossRefGoogle ScholarPubMed
UK Health Departments. Immunisation against infectious disease. London: HMSO, 1996. Google ScholarPubMed
McGregor, J, Marks, PJ, Hayward, A, Bell, Y, Slack, RCB. Factors influencing hepatitis B vaccine uptake in injecting drug users. J Public Health Med 2003;25:165–170. CrossRefGoogle ScholarPubMed
Wiley, TE, McCarthy, M, Breide, L, McCarthy, M, Layden, JT. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805–809. CrossRefGoogle ScholarPubMed
Pessione, F, Degos, F, Marcellin, Pet al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717–1722. CrossRefGoogle ScholarPubMed
Powell, EE, Johnson, JR, Clouston, AD. Steatosis: co-factor in other liver diseases. Hepatology 2005;42:5–13. CrossRefGoogle ScholarPubMed
Bressler, BL, Guindi, M, Tomlinson, G, Heathcote, J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639–644. CrossRefGoogle ScholarPubMed
Seef, LB, Miller, RN, Rabkin, CSet al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105–111. CrossRefGoogle Scholar
Marcellin, P, Boyer, N, Gervais, Aet al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875–881. CrossRefGoogle Scholar
Hoofnagle, JH, Mullen, KD, Jones, DBet al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Eng J Med 1986;315:1575–1578. CrossRefGoogle ScholarPubMed
Poynard, T, Marcellin, P, Lee, SSet al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426–1432. CrossRefGoogle Scholar
Fried, MW, Shiffman, ML, Reddy, KRet al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002;347:975–982. CrossRefGoogle ScholarPubMed
Manns, MP, McHutchinson, JG, Gordon, SCet al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of hepatitis C: a randomised trial. Lancet 2001;358:958–965. CrossRefGoogle ScholarPubMed
Hadziyannis, SJ, Sette, H, Morgan, TRet al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004;130:346–355. CrossRefGoogle Scholar
Hasan, F, Asker, H, Al-Khaldi, Jet al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733–1737. CrossRefGoogle ScholarPubMed
Muir, AJ, Bornstein, JD, Killenberg, PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Eng J Med 2004;350:2265–2271. CrossRefGoogle ScholarPubMed
Backmund, M, Meyer, K, Von Zielonka, M, Eichenlaub, D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188–193. CrossRefGoogle ScholarPubMed
Jowett, SL, Agarwal, K, Smith, BCet al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001;94:153–158. CrossRefGoogle ScholarPubMed
Mauss, S, Berger, F, Goelz, J, Jacob, B, Schmutz, G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120–124. CrossRefGoogle ScholarPubMed
Edlin, BR, Seal, KH, Lorvick, Jet al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Eng J Med 2001;345:211–214. CrossRefGoogle ScholarPubMed
Sheerin, IG, Green, FT, Sellman, JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev 2004;23:261–272. Google ScholarPubMed
Miller, NH. Compliance with treatment regimes in chronic asymptomatic diseases. Am J Med 1997;102:43–49. CrossRefGoogle Scholar
McHutchinson, JG, Manns, M, Patel, Ket al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061–1069. CrossRefGoogle Scholar
Cournot, M, Glibert, A, Castel, Fet al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533–539. CrossRefGoogle ScholarPubMed
De Bie, J, Robaeys, G, Buntinx, F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (ivdu): guidelines for clinical practice. Acta Gastroenterol Belg 2005;68:68–80. Google ScholarPubMed
Golub, ET, Latka, M, Hagan, Het al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004;81:278–290. CrossRefGoogle ScholarPubMed
Mehta, SH, Cox, A, Hoover, DRet al. Protection against persistence of hepatitis C. Lancet 2002;359:1478–1483. CrossRefGoogle ScholarPubMed
Davis, GL, Rodrigue, JR. Treatment of chronic hepatitis C in active drug users. N Eng J Med 2001;345:215–217. CrossRefGoogle ScholarPubMed
Dalgard, O, Bjoro, K, Hellum, Ket al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002;8:45–49. CrossRefGoogle Scholar
Everson, GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol 2005;42:S65–S74. CrossRefGoogle ScholarPubMed
Ryder, SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52(Suppl III):iii1–iii8. CrossRefGoogle ScholarPubMed
Bruix, J, Sherman, M, Llovet, JMet al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421–430. CrossRefGoogle ScholarPubMed
Heathcote, EJ, Shiffman, ML, Cooksley, WGet al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med 2000;343:1673–1680. CrossRefGoogle ScholarPubMed
Everson, GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:905–915. CrossRefGoogle ScholarPubMed
Crippin, JS, McCashland, T, Terrault, N, Sheiner, P, Charlton, MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350–355. CrossRefGoogle ScholarPubMed
Mackie, J, Groves, K, Hoyle, Aet al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001;7:418–427. CrossRefGoogle ScholarPubMed
Levenson, JL, Olbrisch, ME. Psychosocial evaluation of organ transplant candidates: a comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychosomatics 1993;34:314–323. CrossRefGoogle Scholar
Weinrieh, RM, Barnett, R, Lynch, KG, DePiano, M, Atanda, A, Olthoff, KM. A matched comparison study of medical and psychiatric complications and anaesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004;10:97–106. CrossRefGoogle Scholar
Poynard, T, Regimbeau, C, Myers, RPet al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; 1; CD000369. Google Scholar
Jaeckel, E, Cornberg, M, Wedemeyer, Het al. Treatment of acute hepatitis C with interferon alfa-2b. N Eng J Med 2001;345:1452–1457. CrossRefGoogle ScholarPubMed
Villano, SA, Vlahov, D, Nelson, KEet al. Persistence of viraemia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908–914. CrossRefGoogle ScholarPubMed
Gerlach, JT, Diepolder, HM, Zachoval, Ret al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80–88. CrossRefGoogle ScholarPubMed
Jauncey, M, Micallef, JM, Gilmour, Set al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004;190:1270–1274. CrossRefGoogle ScholarPubMed
Broers, B, Helbling, B, Francois, Aet al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323–328. CrossRefGoogle ScholarPubMed
Clarke, SM, Mulcahy, FM. What’s new for injection drug users with HIV infection? Sex Transm Infect 2003;79:80–83. CrossRefGoogle ScholarPubMed
Benhamou, Y, Bochet, M, Di Martino, Vet al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054–1058. CrossRefGoogle ScholarPubMed
Torriani, FJ, Rodriguez-Torres, M, Rockstroh, JKet al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 2004;351:438–450. CrossRefGoogle ScholarPubMed
Chung, RT, Andersen, J, Volberding, Pet al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Eng J Med 2004;351:451–459. CrossRefGoogle ScholarPubMed